2012 TR35 Judges
Ed Boyden*
Leader, Synthetic Neurobiology Group, MIT
Yet-Ming Chiang
Professor of ceramics, MIT
James J. Collins*
Professor of biomedical engineering, Boston University
Stephen H. Friend
President, co-founder, and director, Sage Bionetworks
Javier García-Martínez*
Professor of inorganic chemistry, University of Alicante
Eric Horvitz
Scientist and managing director, Microsoft Research
Alex Huang*
Director, FREEDM Systems Center, North Carolina State University
Ed Lazowska
Bill & Melinda Gates chair in computer science and engineering, University of Washington
Johnny Chung Lee*
Human-Computer Interaction researcher, Google
Christopher B. Murray*
Professor of chemistry, materials science, and engineering, University of Pennsylvania
Dipankar Raychaudhuri
Professor II and director of Winlab, Rutgers University
Chris R. Somerville
Director, Energy Biosciences Institute, University of California, Berkeley
Nimmi Ramanujam*
Professor of biomedical engineering, Duke University
John Rogers*
Professor of materials science, engineering, and chemistry, University of Illinois at Urbana-Champaign
Phillip A. Sharp
Institute professor, MIT
Bjarne Stroustrup
Professor and college of engineering chair in computer science, Texas A&M University
Jennifer West*
Professor of bioengineering, chemical, and biomolecular engineering, Rice University
Paul Wicks*
Director of research and development, PatientsLikeMe
Jackie Ying*
Executive director, Institute of Bioengineering and Nanotechnology
Ben Y. Zhao*
Associate professor of computer science, University of California, Santa Barbara
*Past TR100/TR35 honoree
Keep Reading
Most Popular
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.